Navigation Links
Archimedes Pharma US Announces New US Headquarters In Bedminster, New Jersey

READING, England and BEDMINSTER, N.J., Aug. 23 /PRNewswire/ -- Archimedes Pharma, an emerging specialty pharma company focused on oncology, pain, neurology and critical care sectors, announced today the location of its new US headquarters in Bedminster, New Jersey.

Archimedes has offices in a number of European countries and markets a range of therapeutics in Europe.  The opening of its US office marks the continued expansion of the company's global commercial presence.  The New Jersey location will provide Archimedes access to the deep resource pool of New Jersey-based specialty pharma professionals.  Archimedes will add a significant number of positions this year, including sales & marketing, regulatory, finance, human resources and medical affairs.

The New Jersey Economic Development Authority awarded a Business Employment Incentive Program (BEIP) grant for Archimedes Pharma US to create up to 75 new jobs.  BEIP grants are available to businesses looking to expand or relocate while creating job growth in New Jersey.

Jeffrey H. Buchalter, President and CEO of Archimedes Pharma, reaffirmed Archimedes' commitment to New Jersey and said, "The new US headquarters in Bedminster is a significant milestone in Archimedes' development as an emerging global specialty pharmaceutical company.  With Archimedes' rapidly growing and diverse drug delivery technologies and products portfolio, we are in the process of establishing our own US organization and are actively recruiting top-tier senior-level management positions to support market penetration across the USA and globally. The BEIP grant awarded to us by the state was the deciding factor when choosing a US location.  We're committed to New Jersey and growth of the pharmaceutical business here."

Archimedes' lead product, PecFent®, an innovative fentanyl nasal spray for the treatment of breakthrough cancer pain, received a Positive Opinion from the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) in June 2010.  A New Drug Application (NDA) for the drug was submitted to the US Food and Drug Administration (FDA) in August 2009; discussions with the FDA are ongoing.  

About Archimedes PharmaArchimedes Pharma is a specialty pharmaceutical company marketing and selling an expanding portfolio of specialist products to hospital-based prescribers in major European territories.

Focused on the oncology, pain, neurology and critical care sectors, Archimedes currently markets multiple therapeutics in the UK, France, Germany and Ireland. The company is expanding its commercial presence in Spain and the US.

Products currently marketed in Europe by Archimedes include: Gliadel, a biodegradable wafer impregnated with carmustine for high-grade glioma; Zomorph, an oral sustained release morphine product for moderate to severe pain, particularly cancer pain; Oramorph, a liquid immediate release morphine product also indicated for moderate to severe pain; Apomorphine Injection for motor fluctuations in advanced Parkinson's disease; and Pabrinex, a high potency vitamin formulation used to treat the symptoms of malnutrition especially in patients with alcohol misuse problems.

Archimedes is also developing a robust, high-value pipeline of in-house pain therapeutics, Parkinson's disease and critical care.  It applies its world-class drug delivery technologies to proven molecules that have yet to achieve their market potential due to their current mode of delivery. This approach reduces the company's development risk, while delivering significant clinical and commercial benefits.

PecFent®Archimedes' lead product is PecFent, an innovative and highly differentiated fentanyl citrate nasal spray, which has been granted a Positive Opinion by the CHMP for the treatment of breakthrough cancer pain.

PecFent is an aqueous fentanyl citrate solution utilizing Archimedes' proprietary PecSys™ technology. The PecFent solution has a low viscosity and is easily delivered in a low volume of 100mcl using a nasal spray pump. The pump produces a fine mist of similarly sized spray droplets that are deposited into the front of the nostril. The calcium ions present on the nasal mucosa cause the pectin to form a thin gel layer, which allows fentanyl to be retained on the nasal mucosa, allowing a rapid but controlled absorption into the systemic circulation. The PecSys™ technology avoids problems associated with simple solutions used in nasal sprays, such as dripping or swallowing of the drug solution.

Archimedes' technologies - ChiSys®, PecSys™ and TARGIT® - are also used in a number of partnered products in late-stage clinical development. ChiSys, an innovative drug delivery technology that enhances the residence time of molecules on mucosal membranes, has proven potential for vaccine delivery. Pre-clinical and clinical studies of nasally administered vaccines have demonstrated enhanced immune response. PecSys™ is Archimedes' patented drug delivery system built around its novel pectin technology, designed to maximize the potential of systemically absorbed drugs by enhancing drug performance and improving patient acceptance.

About Breakthrough Cancer Pain (BTCP)Breakthrough cancer pain affects up to 95% of all cancer patients with pain and is characterized by sudden, unpredictable episodes of intense pain that occur despite background pain medication. This pain is rapid in onset, usually reaching maximum intensity in five minutes and lasting for 30 to 60 minutes.

For more information, please visit: contacts:Tiberend Strategic Advisors, Inc. (USA) Tamara Bright/Andrew Mielach, +1 212-827-0020 Citigate Dewe Rogerson (UK and Europe) Chris Gardner/Amber Bielecka, +44 207 638 9571

SOURCE Archimedes Pharma
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
3. Par Pharmaceutical Reports Second Quarter 2008 Results
4. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Best Practice Database Supports Bio-Pharma Product Launch
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Huifeng Bio-Pharmaceutical (HFGB) Announces USD $1.1 Million Supply Agreement with DNP International Co. Inc.
10. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
11. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... ... that includes over 2,000 technical presentations offered in symposia, oral sessions, workshops, awards, ... spectroscopy, covers a wide range of applications such as, but not limited to, ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> Accutest Research Laboratories, ... Contract Research Organization (CRO), has formed ... Cancer Center - Temple Health for ... ,     (Photo: ) , ...
(Date:11/25/2015)... November 26, 2015 ... Market 2016 - 2020 report analyzes that automating ... and quality in long-term samples, minimizing manual errors, ... Automation minimizes manual errors such as mislabeling or ... Further, it plays a vital role in blood ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:11/16/2015)... SAN JOSE, Calif. , Nov 16, 2015 ... leading developer of human interface solutions, today announced ... new Synaptics TouchView ™ touch controller and ... the architectural revolution of smartphones. These new TDDI ... and include TD4100 (HD resolution), TD4302 (WQHD resolution), ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , an ... of clinical research, is pleased to announce that it will ... Trials (PCT) event, to be held November 17-19 in ... to view live demonstrations of iMedNet , ... how iMedNet has been able to deliver time ...
(Date:11/9/2015)... Calif. , Nov. 9, 2015  Synaptics Inc. ... interface solutions, today announced broader entry into the automotive ... solutions that match the pace of consumer electronics human ... biometric sensors are ideal for the automotive industry and ... Europe , ...
Breaking Biology News(10 mins):